Drug Trial Radar · NCT07414290
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
17
Planned (sponsor's estimate)
Start
May 25, 2026
Primary completion
Sep 1, 2027
Study completion Sep 1, 2031
Sponsor
- Lead sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R08b Intra-cerebroventricular injection in Parkinson's Disease Patients with GBA1 Mutations
Conditions
- Parkinson Disease (PD)
Interventions
VGN-R08b 4.2×10^13 vgDrug
Intracerebroventricular injection
VGN-R08b 8.4×10^13 vgDrug
Intracerebroventricular injection
VGN-R08b 1.68×10^14 vgDrug
Intracerebroventricular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs), Serious Adverse Events (SAEs)Vital signsTime frame: up to Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital, Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.